. 2023 May 24;24(11):9210. doi: 10.3390/ijms24119210

Table 1.

The frequency of detection of the MPO-DNA complex in patients with SLE depending on clinical manifestations.

Parameter		MPO-DNA Complex (+), n = 30, n (%)	MPO-DNA Complex (-), n = 47, n (%)	χ²; p OR and 95% CI
Lupus nephritis	yes	20 (67)	17 (36)	6.82; 0.009 3.53 [1.35–9.26]
Lupus nephritis	no	10 (33)	30 (64)	6.82; 0.009 3.53 [1.35–9.26]
Positive antibodies to dsDNA	yes	26 (87)	30 (64)	4.82; 0.036 3.68 [1.09–12.34]
Positive antibodies to dsDNA	no	4 (13)	17 (36)	4.82; 0.036 3.68 [1.09–12.34]
Hypocomplementemia	yes	23 (77)	22 (47)	6.72; 0.01 3.73 [1.34–10.37]
Hypocomplementemia	no	7 (23)	25 (53)	6.72; 0.01 3.73 [1.34–10.37]
High SLE activity	yes	13 (43)	9 (19)	5.25; 0.037 3.23 [1.16–8.99]
High SLE activity	no	17 (57)	38 (81)	5.25; 0.037 3.23 [1.16–8.99]

Note: MPO-DNA complex, myeloperoxidase–deoxyribonucleic acid complex; χ², agreement criterion; p, probability; OR, odds ratio; CI, confidence interval; anti-dsDNA, anti-double-stranded DNA; SLE, systemic lupus erythematosus.